Literature DB >> 21042046

Insulin resistance explains the relationship between novel cardiovascular risk factors and hypertension. The Telde Study.

A M Wägner1, J C Wiebe, M Boronat, P Saavedra, D Marrero, F Varillas, F J Nóvoa.   

Abstract

BACKGROUND: Most studies describing an association between hypertension and an inflammatory/pro-thrombotic state do not assess insulin resistance. AIM: To examine the association between hypertension and new cardiovascular risk factors when considering both classical risk factors and insulin resistance.
METHODS: In a population-based sample of 1030 subjects, clinical information and blood samples were obtained. Subjects were classified according to the presence or absence of hypertension, and insulin resistance was estimated using the homeostasis model of assessment (HOMA). To identify variables independently associated with hypertension, a four-model multiple logistic regression was performed: model 1 included novel risk factors (Plasminogen Activator Inhibitor- 1 [PAI-1], fibrinogen, von Willebrand Factor [vWF], lipoprotein(a), homocysteine and C-reactive Protein [CRP]); model 2, novel risk factors plus HOMA; model 3 included both classical (smoking, triglycerides, HDL cholesterol, total cholesterol, waist circumference and diabetes) and novel risk factors and model 4, model 3 plus HOMA. All were adjusted for age, BMI and gender and compared using Akaike's Information Criterion (AIC).
RESULTS: In model 1, only PAI-1, age and BMI showed association with hypertension.When HOMA and classical risk factors were also included, PAI-1 was replaced by triglyceride, smoking and diabetes. The lowest AIC value (best adjustment) was displayed by model 4, comprising all of the variables. Only age, BMI, HOMA and smoking remained significantly associated with hypertension.
CONCLUSIONS: The novel cardiovascular risk factors assessed do not add information as markers of hypertension when classical risk factors or insulin resistance are included in the evaluation.

Entities:  

Mesh:

Year:  2010        PMID: 21042046     DOI: 10.3275/7325

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  33 in total

1.  Differences in cardiovascular risk factors, insulin resistance, and insulin secretion in individuals with normal glucose tolerance and in subjects with impaired glucose regulation: the Telde Study.

Authors:  Francisco J Nóvoa; Mauro Boronat; Pedro Saavedra; Juan M Díaz-Cremades; Valois F Varillas; Fátima La Roche; María P Alberiche; Armando Carrillo
Journal:  Diabetes Care       Date:  2005-10       Impact factor: 19.112

2.  Elevation of plasminogen activator inhibitor 1 in borderline hypertension is linked to concomitant metabolic disturbances.

Authors:  C Lemne; U De Faire
Journal:  Eur J Clin Invest       Date:  1996-08       Impact factor: 4.686

3.  Multiple biomarkers and the risk of incident hypertension.

Authors:  Thomas J Wang; Philimon Gona; Martin G Larson; Daniel Levy; Emelia J Benjamin; Geoffrey H Tofler; Paul F Jacques; James B Meigs; Nader Rifai; Jacob Selhub; Sander J Robins; Christopher Newton-Cheh; Ramachandran S Vasan
Journal:  Hypertension       Date:  2007-01-22       Impact factor: 10.190

4.  Is the plasminogen activator inhibitor-1 gene a candidate gene predisposing to hypertension? Results from a population-based study in Spain.

Authors:  María J Martínez-Calatrava; José L González-Sánchez; Carina Zabena; María T Martínez-Larrad; Manuel Luque-Otero; Manuel Serrano-Ríos
Journal:  J Hypertens       Date:  2007-04       Impact factor: 4.844

5.  PAI-1 in human hypertension: relation to hypertensive groups.

Authors:  Nadarajah Srikumar; Nancy J Brown; Paul N Hopkins; Xavier Jeunemaitre; Steven C Hunt; Douglas E Vaughan; Gordon H Williams
Journal:  Am J Hypertens       Date:  2002-08       Impact factor: 2.689

6.  Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes.

Authors:  Andreas Festa; Ken Williams; Russell P Tracy; Lynne E Wagenknecht; Steven M Haffner
Journal:  Circulation       Date:  2006-04-03       Impact factor: 29.690

7.  C-reactive protein and the risk of developing hypertension.

Authors:  Howard D Sesso; Julie E Buring; Nader Rifai; Gavin J Blake; J Michael Gaziano; Paul M Ridker
Journal:  JAMA       Date:  2003-12-10       Impact factor: 56.272

8.  New atherosclerosis risk factors in obese, hypertensive and diabetic children and adolescents.

Authors:  Barbara Glowinska; Miroslawa Urban; Alicja Koput; Marzena Galar
Journal:  Atherosclerosis       Date:  2003-04       Impact factor: 5.162

9.  Metabolic syndrome and target organ damage in untreated essential hypertensives.

Authors:  Cesare Cuspidi; Stefano Meani; Veronica Fusi; Barbara Severgnini; Cristiana Valerio; Eleonora Catini; Gastone Leonetti; Fabio Magrini; Alberto Zanchetti
Journal:  J Hypertens       Date:  2004-10       Impact factor: 4.844

Review 10.  Insulin resistance, hypertension, and coronary heart disease.

Authors:  Gerald Reaven
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Jul-Aug       Impact factor: 3.738

View more
  2 in total

Review 1.  Hypogonadism and metabolic syndrome.

Authors:  G Corona; G Rastrelli; A Morelli; L Vignozzi; E Mannucci; M Maggi
Journal:  J Endocrinol Invest       Date:  2011-06-27       Impact factor: 4.256

2.  A Common Variant at the 3'untranslated Region of the CCL7 Gene (rs17735770) Is Associated With Decreased Susceptibility to Coronary Heart Disease.

Authors:  José María Medina-Gil; Ana Pérez-García; Pedro Saavedra-Santana; Asunción Díaz-Carrasco; Efrén Martínez-Quintana; Fayna Rodríguez-González; Cristina M Ramírez; Marta Riaño; Paloma Garay-Sánchez; Antonio Tugores
Journal:  Front Cardiovasc Med       Date:  2022-05-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.